Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Trial: Effect of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement on the Nutritional and Inflammatory Status, Quality of Life, Toxicity and Response Rate to First-line Chemotherapy in Patients With Advanced Lung Cancer

NCT01048970 is registered in ClinicalTrials.gov with National Institute of Cancerología as lead sponsor.

NCT NCT01048970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01048970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Trial: Effect of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement on the Nutritional and Inflammatory Status, Quality of Life, Toxicity and Response Rate to First-line Chemotherapy in Patients With Advanced Lung Cancer
Lead sponsor
National Institute of Cancerología
Phase
Phase 2/3
Overall status
Unknown status
Start date
October 31, 2009
Completion date
December 31, 2010
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer